Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:

NCT ID: NCT01240928 Withdrawn - Clinical trials for Metastatic Breast Cancer

MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

Start date: n/a
Phase: Phase 1
Study type: Interventional

This is a phase Ib trial that evaluates the safety and tolerability of MK-2206 given in combination with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor-positive metastatic breast cancer.

NCT ID: NCT01134497 Withdrawn - Clinical trials for Metastatic Breast Cancer

Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer

PLANET
Start date: n/a
Phase: Phase 2
Study type: Interventional

In this "randomised Phase II trial" all patients will receive carboplatin, with half randomly selected to receive ZD4054. The other half to also receive a dummy pill or placebo, this is so that we can accurately assess how much extra benefit ZD4054 may give. The trial will recruit 132 patients with metastatic breast cancer from across the UK and assess whether adding ZD4054 to carboplatin delays progression of their disease. It will also show whether the side effects of adding ZD4054 to carboplatin chemotherapy are acceptable. Because ZD4054 has not previously been given with carboplatin to this population, in Stage 1 of the study 6 patients will receive ZD4054 with carboplatin. If there are no untoward side effects with carboplatin and ZD4054 then the trial will proceed to Stage 2 and a further 126 patients will be randomised to receive carboplatin with either ZD4054 or the placebo; neither the patient nor their doctor will know whether she is receiving ZD4054 or placebo.

NCT ID: NCT00380835 Withdrawn - Clinical trials for Metastatic Breast Cancer

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.